IgA Vasculitis: A Comprehensive Medical Guide

1. Introduction & Overview

IgA vasculitis, formerly known as Henoch-Schönlein purpura (HSP), is the most common childhood systemic vasculitis. It is a small-vessel vasculitis characterized by the deposition of immune complexes containing immunoglobulin A (IgA) within the walls of small blood vessels, primarily affecting the skin, joints, gastrointestinal tract, and kidneys. While it can occur at any age, it is most frequently diagnosed in children between the ages of 3 and 15 years, with a slight male predominance. The condition is typically self-limiting, with most cases resolving within weeks to months. However, a significant minority of patients, particularly those with severe renal involvement, can experience long-term complications, including chronic kidney disease. Understanding the nuances of IgA vasculitis is crucial for accurate diagnosis, effective management, and optimal patient outcomes.

This comprehensive guide aims to provide an in-depth understanding of IgA vasculitis, covering its clinical definition, etiology, pathophysiology, clinical presentation, diagnostic approaches, and prognosis. It is intended for healthcare professionals, including pediatricians, rheumatologists, nephrologists, and general practitioners, as well as for patients and their families seeking detailed information about this condition.

2. Clinical Definition, Etiology, and Pathophysiology

2.1. Clinical Definition

IgA vasculitis is defined as a systemic vasculitis characterized by IgA-containing immune complex deposition in small blood vessels. The diagnostic criteria, as established by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR), generally require the presence of palpable purpura in the absence of other identifiable causes, plus at least one of the following:
* Arthritis or arthralgia: Typically affecting the lower extremities.
* Abdominal pain: Often colicky and severe, leading to nausea, vomiting, and sometimes gastrointestinal bleeding.
* Renal involvement: Manifesting as hematuria, proteinuria, or active urinary sediment.
* Biopsy findings: Demonstrating IgA deposition in small vessels, often with leukocytoclastic vasculitis.

2.2. Etiology

The exact etiology of IgA vasculitis remains largely unknown, and it is considered a multifactorial disease. However, several triggers and predisposing factors have been identified:

• Infections: This is the most common precipitating factor, particularly upper respiratory tract infections (URTIs) caused by Streptococcus pyogenes (Group A Streptococcus). Other identified triggers include viral infections (e.g., parvovirus B19, adenovirus, enteroviruses, hepatitis B and C) and bacterial infections (e.g., Helicobacter pylori). The immune response to these infections is thought to lead to the formation of IgA-containing immune complexes.
• Allergens and Drugs: Less commonly, IgA vasculitis has been associated with exposure to certain foods (e.g., cow's milk, eggs, wheat), insect bites, and medications (e.g., ACE inhibitors, antibiotics, NSAIDs).
• Genetic Predisposition: Certain HLA-B27 alleles and other genetic factors may confer an increased susceptibility to developing IgA vasculitis, especially in individuals exposed to specific triggers.
• Autoimmunity: While not a classic autoimmune disease, there is evidence of dysregulation in the immune system, leading to aberrant IgA production and immune complex formation.

2.3. Pathophysiology

The hallmark of IgA vasculitis is the deposition of IgA-containing immune complexes in the walls of small blood vessels, particularly venules and capillaries. This process involves several key steps:

1. Immune Complex Formation: Following an initial trigger (e.g., infection), there is an abnormal increase in IgA production, particularly IgA1. These IgA antibodies may be directed against self-antigens or microbial antigens. These antigens bind to IgA, forming immune complexes.
2. Immune Complex Deposition: These circulating immune complexes are deposited in the subendothelial space of small blood vessels. Factors such as altered glycosylation of IgA1 (resulting in increased galactose-deficient IgA1 or Gd-IgA1) and complement activation (particularly the alternative pathway) are thought to play a role in their deposition.
3. Inflammation and Vasculitis: The deposited immune complexes activate the complement system, leading to the generation of anaphylatoxins (C3a, C5a) and chemotactic factors. These mediators recruit inflammatory cells, including neutrophils and macrophages, to the vessel walls.
4. Endothelial Cell Activation and Damage: Inflammatory cells release proteases, cytokines, and reactive oxygen species, causing endothelial cell activation, damage, and increased vascular permeability. This leads to leukocytoclastic vasculitis, characterized by inflammation and damage to small blood vessels.
5. Organ Involvement:
   • Skin: The deposition of immune complexes in dermal capillaries causes increased permeability, leading to extravasation of red blood cells and the characteristic palpable purpura.
   • Joints: Inflammation in the synovial membranes and surrounding tissues results in arthritis or arthralgia.
   • Gastrointestinal Tract: Similar inflammatory processes in the mesenteric blood vessels can lead to edema, submucosal hemorrhage, and ulceration, causing abdominal pain and GI bleeding. Intussusception is a rare but serious complication.
   • Kidneys: The glomeruli are particularly susceptible to IgA deposition. Immune complexes in the glomerular capillaries trigger a cascade of inflammatory events, including mesangial cell proliferation, endocapillary proliferation, and crescent formation, leading to glomerulonephritis.

3. Clinical Presentation

The presentation of IgA vasculitis can vary significantly in severity and organ involvement. The classic tetrad of symptoms includes:

3.1. Cutaneous Manifestations (Purpura)

• Palpable Purpura: This is the hallmark of IgA vasculitis and is present in virtually all patients. It typically appears as erythematous to violaceous, non-blanching papules and macules, often progressing to petechiae and ecchymoses.
• Distribution: The lesions characteristically affect dependent areas, particularly the buttocks, lower extremities (ankles, calves, thighs), and elbows. They are less common on the trunk or upper extremities.
• Evolution: The purpura may appear in crops over several days to weeks and can resolve with hyperpigmentation, sometimes leaving residual scarring.

3.2. Arthritic Manifestations (Arthritis/Arthralgia)

• Arthralgia: Joint pain is very common, reported in 70-85% of patients.
• Arthritis: Inflammatory arthritis occurs in 50-75% of patients. It is typically migratory, oligoarticular (affecting a few joints), and non-deforming.
• Affected Joints: The most commonly involved joints are the ankles and knees, followed by the wrists and elbows.
• Resolution: Joint symptoms usually resolve completely within days to weeks without causing permanent damage.

3.3. Gastrointestinal Manifestations (Abdominal Pain)

• Abdominal Pain: Present in 50-75% of patients, this is often colicky, diffuse, and can be severe.
• Associated Symptoms: Nausea, vomiting, and anorexia are common.
• Gastrointestinal Bleeding: Occurs in about 20-30% of patients and can range from occult blood in the stool to overt melena or hematochezia.
• Complications: Rare but serious complications include intestinal intussusception (more common in younger children), perforation, and obstruction.

3.4. Renal Manifestations (Glomerulonephritis)

• Renal Involvement: Occurs in 25-50% of patients and is the most significant predictor of long-term prognosis.
• Clinical Manifestations:
  • Hematuria: Microscopic or macroscopic.
  • Proteinuria: Mild to moderate.
  • Active Urinary Sediment: Presence of red blood cell casts, white blood cells, and dysmorphic red blood cells.
  • Hypertension: Can occur in more severe cases.
  • Acute Kidney Injury (AKI): In severe cases, leading to oliguria and elevated serum creatinine.
• Severity: Most renal involvement is mild and resolves within weeks. However, a subset of patients can develop progressive renal disease, leading to chronic kidney disease (CKD) and end-stage renal disease (ESRD).

4. Clinical Staging/Grading

While there isn't a universally adopted formal staging system for IgA vasculitis, clinical grading is often based on the severity of organ involvement, particularly renal and gastrointestinal manifestations. A common approach categorizes patients into:

• Mild: Primarily cutaneous and joint symptoms, with minimal or absent renal and GI involvement.
• Moderate: Significant GI symptoms (e.g., severe pain, bleeding) and/or mild to moderate renal involvement (e.g., isolated hematuria/proteinuria).
• Severe: Severe GI complications (e.g., intussusception, perforation) and/or significant renal involvement (e.g., active urinary sediment, rising creatinine, nephrotic syndrome, crescentic glomerulonephritis).

The presence and severity of renal involvement are the most critical factors determining long-term prognosis.

5. Differential Diagnosis

Given the multisystemic nature of IgA vasculitis, a broad differential diagnosis must be considered. Key conditions to rule out include:

| Condition | Key Differentiating Features